Merck just closed its Terns deal

Deal closed, now the real work starts

Merck says the acquisition of Terns Pharmaceuticals is officially done. In plain English: the paperwork is signed, the integration dance begins, and Terns is now part of Merck's science empire.

Why Merck wanted it

This isn't Merck buying a random lab coat and a coffee machine. The company says the deal fits its strategy of making "science-driven, value-enhancing" bets — corporate speak for: we want assets that can actually move the needle.

Terns' lead candidate, TERN-701, is the shiny object here. Merck clearly sees potential, and that's the part investors will be watching: can this asset become more than just another slide in a presentation deck?

What to watch next

• How quickly Merck folds Terns' programs into its broader pipeline
• Whether TERN-701 gets more development firepower under Merck
• If this deal turns into a meaningful growth lever, or just another small bolt-on

Big picture: Merck is still trying to build the next chapter around its pipeline, because eventually the Keytruda-era party has to end.